AMTX AEMETIS, INC
Industrial Organic Chemicals · Nasdaq · SEC CIK 738214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.6%
TTM net income YoY64.5%
TTM EPS YoY73.5%
Revenue 3-yr CAGR10.8%
Net income 3-yr CAGR—
Margins
Gross margin21.5%
Operating margin7.2%
Net margin-12.5%
FCF margin-14.7%
EBITDA margin11.3%
Returns
ROE—
ROA-11.3%
ROIC (approx.)17.5%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets200.7%
Debt / equity—
Current ratio0.07x
Interest coverage0.32x
Cash quality & payout
Operating cash flow / net income-0.49x
Accruals ratio-16.8%
Payout ratio—
Capex / revenue20.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $197.63M | $267.64M |
| Cost of revenue | $208.75M | $268.22M |
| Gross profit | -$768,000 | -$580,000 |
| SG&A expense | $36.45M | $39.84M |
| Operating income | -$37.22M | -$40.42M |
| Interest expense | $52.91M | $46.62M |
| Pretax income | -$95.75M | -$98.37M |
| Income tax | -$18.75M | -$10.83M |
| Net income | -$77.00M | -$87.54M |
| EBITDA | -$27.59M | -$32.03M |
| EPS (basic) | -1.28 | -1.91 |
| EPS (diluted) | -1.28 | -1.91 |
| Weighted avg. shares (diluted) | 59.98M | 45.90M |
| Balance sheet | ||
| Cash & equivalents | $4.89M | $898,000 |
| Inventory | $11.63M | $25.44M |
| Current assets | $26.87M | $44.70M |
| PP&E, net | $219.72M | $199.39M |
| Total assets | $259.84M | $259.30M |
| Current liabilities | $371.26M | $143.97M |
| Short-term debt | $317.87M | $90.53M |
| Long-term debt | $63.90M | $247.53M |
| Total debt | $381.76M | $338.06M |
| Total liabilities | $566.67M | $523.23M |
| Shareholders' equity | -$306.83M | -$263.93M |
| Net debt | $376.87M | $337.16M |
| Shares outstanding | 66.19M | 51.14M |
| Cash flow statement | ||
| Operating cash flow | $3.26M | -$32.93M |
| Capital expenditure | $26.00M | $20.25M |
| Free cash flow | -$22.74M | -$53.18M |
| Investing cash flow | -$25.59M | -$14.15M |
| Financing cash flow | $26.41M | $44.62M |
| Depreciation & amortization | $9.62M | $8.39M |
| Stock-based compensation | $5.77M | $8.31M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.